25 August 2016Big Pharma

Video interview: Hogan Lovells discusses implications of Brexit on SPCs

In an exclusive interview with LSIPR, Stephen Bennett, partner at Hogan Lovells, talks about the implications of Brexit with a focus on supplementary protection certificates (SPCs).

Bennett also covers the challenges facing SPC owners, how they should be tackled, and what SPC owners can do to minimise any negative impact of Brexit.

More on this story

Big Pharma

A clearer picture for SPCs?

8 October 2015 The CJEU’s decision on how an SPC term is to be determined is likely to be welcomed by applicants and owners, but the court has left them to work out how to apply the ruling, say Natalia Wegner-Cribbs and Daniel Wise of Carpmaels & Ransford.

Biotechnology

CJEU adviser to give opinion on SPC term

9 September 2015 An adviser at Europe’s highest court is expected to issue an opinion on whether the term of a supplementary protection certificate begins once it is authorised or when the applicant has been notified about it.